Zymeworks Inc. Appoints New Directors, Adjusts Executive Compensation
Ticker: ZYME · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1937653
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Zymeworks adds 2 directors, tweaks exec pay. Board shakeup incoming.
AI Summary
Zymeworks Inc. announced on August 30, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Paul J. Hastings and Ms. Jennifer L. D. Good, to its Board of Directors, effective immediately. Additionally, the company entered into new employment agreements with certain executive officers, including a new employment agreement with its Chief Medical Officer, Dr. Neil Gallagher.
Why It Matters
The appointment of new directors and adjustments to executive compensation can signal strategic shifts or changes in leadership focus for Zymeworks Inc., potentially impacting its future direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal restructuring or strategic realignments, which may carry inherent risks.
Key Players & Entities
- Zymeworks Inc. (company) — Registrant
- Dr. Paul J. Hastings (person) — Newly Elected Director
- Ms. Jennifer L. D. Good (person) — Newly Elected Director
- Dr. Neil Gallagher (person) — Chief Medical Officer
- August 30, 2024 (date) — Date of earliest event reported
FAQ
Who were the new directors elected to Zymeworks Inc.'s Board of Directors?
Dr. Paul J. Hastings and Ms. Jennifer L. D. Good were elected as new directors to Zymeworks Inc.'s Board of Directors.
When were the new directors' appointments effective?
The appointments of Dr. Paul J. Hastings and Ms. Jennifer L. D. Good were effective immediately as of August 30, 2024.
What other significant event was reported by Zymeworks Inc. on August 30, 2024?
Zymeworks Inc. also reported entering into new employment agreements with certain executive officers, including its Chief Medical Officer, Dr. Neil Gallagher.
What is the principal executive office address for Zymeworks Inc.?
The principal executive offices of Zymeworks Inc. are located at 108 Patriot Drive, Suite A, Middletown, Delaware.
What is the filing date for this 8-K report?
This 8-K report was filed as of September 3, 2024.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-09-03 16:06:59
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
Filing Documents
- d848190d8k.htm (8-K) — 23KB
- 0001193125-24-212062.txt ( ) — 141KB
- zyme-20240830.xsd (EX-101.SCH) — 3KB
- zyme-20240830_lab.xml (EX-101.LAB) — 18KB
- zyme-20240830_pre.xml (EX-101.PRE) — 11KB
- d848190d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ZYMEWORKS INC. (Registrant) Date: September 3, 2024 By: /s/ Kenneth Galbraith Name: Title: Kenneth Galbraith Chair, Chief Executive Officer and President 3